Liu Jiuyu, Bruhn David F, Lee Robin B, Zheng Zhong, Janusic Tanja, Scherbakov Dimitri, Scherman Michael S, Boshoff Helena I, Das Sourav, Waidyarachchi Samanthi L, Brewer Tiffany A, Gracia Begoña, Yang Lei, Bollinger John, Robertson Gregory T, Meibohm Bernd, Lenaerts Anne J, Ainsa Jose, Böttger Erik C, Lee Richard E
Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital , 262 Danny Thomas Place, MS#1000, Memphis, Tennessee 38105, United States.
Institut für Medizinische Mikrobiologie, Nationales Zentrum für Mykobakterien, Universität Zürich , Rämistrasse 71, Gloriastrasse 30/32, CH-8006 Zürich, Switzerland.
ACS Infect Dis. 2017 Jan 13;3(1):72-88. doi: 10.1021/acsinfecdis.6b00158. Epub 2016 Nov 11.
Spectinamides are a novel class of antitubercular agents with the potential to treat drug-resistant tuberculosis infections. Their antitubercular activity is derived from both ribosomal affinity and their ability to overcome intrinsic efflux mediated by the Mycobacterium tuberculosis Rv1258c efflux pump. This study explores the structure-activity relationships through analysis of 50 targeted spectinamides. Compounds are evaluated for ribosomal translational inhibition, MIC activity in Rv1258c efflux pump deficient and wild type tuberculosis strains, and efficacy in an acute model of tuberculosis infection. The results of this study show a narrow structure-activity relationship, consistent with a tight ribosome-binding pocket and strict structural requirements to overcome native efflux. Rationalization of ribosomal inhibition data using molecular dynamics simulations showed stable complex formation for halogenated spectinamides consistent with the long post antibiotic effects observed. The lead spectinamides identified in this study demonstrated potent MIC activity against MDR and XDR tuberculosis and had desirable antitubercular class specific features including low protein binding, low microsomal metabolism, no cytotoxicity, and significant reductions in bacterial burdens in the lungs of mice infected with M. tuberculosis. The structure-activity relationships detailed here emphasize the need to examine efflux-mediated resistance in the design of antituberculosis drugs and demonstrate that it is possible to overcome intrinsic efflux with synthetic modification. The ability to understand the structure requirements for this class has produced a variety of new substituted spectinamides, which may provide useful alternative candidates and promote the further development of this class.
光谱酰胺是一类新型抗结核药物,具有治疗耐药结核病感染的潜力。它们的抗结核活性源于核糖体亲和力以及克服由结核分枝杆菌Rv1258c外排泵介导的内在外排的能力。本研究通过分析50种靶向光谱酰胺来探索构效关系。对化合物进行核糖体翻译抑制、Rv1258c外排泵缺陷型和野生型结核菌株中的MIC活性以及结核病感染急性模型中的疗效评估。本研究结果显示构效关系狭窄,这与紧密的核糖体结合口袋以及克服天然外排的严格结构要求一致。使用分子动力学模拟对核糖体抑制数据进行合理化分析表明,卤代光谱酰胺形成稳定的复合物,这与观察到的长抗生素后效应一致。本研究中鉴定出的先导光谱酰胺对耐多药和广泛耐药结核病表现出强大的MIC活性,并具有理想的抗结核类特异性特征,包括低蛋白结合、低微粒体代谢、无细胞毒性以及感染结核分枝杆菌的小鼠肺部细菌负荷显著降低。这里详细阐述的构效关系强调了在抗结核药物设计中研究外排介导耐药性的必要性,并证明通过合成修饰有可能克服内在外排。了解此类药物结构要求的能力产生了多种新的取代光谱酰胺,这可能提供有用的替代候选物并促进此类药物的进一步开发。